BeiGene (BGNE) Stock Price, News & Analysis

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BGNE shares.
View BGNE analyst ratings or view top-rated stocks.

10 equities research analysts have issued twelve-month target prices for BeiGene's shares. Their BGNE share price targets range from $161.00 to $345.00. On average, they expect the company's share price to reach $250.13 in the next year. This suggests a possible upside of 73.6% from the stock's current price.
View analysts price targets for BGNE or view top-rated stocks among Wall Street analysts.

BeiGene's stock was trading at $180.36 at the beginning of the year. Since then, BGNE stock has decreased by 20.1% and is now trading at $144.12.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our BGNE earnings forecast.

BeiGene, Ltd. (NASDAQ:BGNE) issued its quarterly earnings results on Monday, February, 26th. The company reported ($3.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.61) by $0.08. The firm had revenue of $634.40 million for the quarter, compared to analyst estimates of $632.52 million. BeiGene had a negative net margin of 35.86% and a negative trailing twelve-month return on equity of 23.12%. The business's revenue for the quarter was up 66.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($4.29) EPS.

ETFs with the largest weight of BeiGene (NASDAQ:BGNE) stock in their portfolio include Morningstar US Small Growth (MSGR), VanEck Biotech ETF (BBH), First Trust NYSE Arca Biotechnology Index Fund (FBT), Tema Oncology ETF (CANC), Virtus LifeSci Biotech Products ETF (BBP), iShares Biotechnology ETF (IBB), Global X Aging Population ETF (AGNG) and Invesco Nasdaq Biotechnology ETF (IBBQ).

58 employees have rated BeiGene Chief Executive Officer John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among the company's employees. 42.0% of employees surveyed would recommend working at BeiGene to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Block (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).

BeiGene (BGNE) raised $126 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company served as the underwriters for the IPO and Baird was co-manager.

BeiGene's stock is owned by many different institutional and retail investors. Top institutional investors include Simplicity Wealth LLC (0.01%), Venturi Wealth Management LLC (0.00%) and LVW Advisors LLC (0.00%). Insiders that own company stock include Advisors Ltd Hhlr, Amgen Inc, Chan Henry Lee, Corazon (Corsee) D Sanders, Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Ltd Beigene, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends.

Shares of BGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.